Changes in diabetes prevalence and treatment in the last ten years in Luxembourg. A lesson from the United Kingdom prospective diabetes study?

Diabetes and Metabolism

Volumn 31, Issue 5, 2005, Pages 499-502

  Perquin, M ^a   Michel, G H ^b   De Beaufort, C ^b   Keipes, M ^c   Wirion, R ^c   Haas, N ^d  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^c Clinique Sainte Therese Luxembourg   (Luxembourg)

^d Luxembourg Scientific Society of General Medicine   (Luxembourg)

Author keywords

Diabetes; Epidemiology; Pharmacology; Prescription attitudes; Prevalence

Indexed keywords

ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; SULFONYLUREA; UNCLASSIFIED DRUG;

ARTICLE; DIABETES MELLITUS; DIET THERAPY; DRUG MARKETING; ENDOCRINOLOGY; GENERAL PRACTITIONER; HUMAN; MEDICAL EDUCATION; PRESCRIPTION; QUESTIONNAIRE; TABLET; UNITED KINGDOM;

EID: 27844558255     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70222-7     Document Type: Review

References (16)

1. King H, Aubert R, Herman W. Global Burden of Diabetes, 1995-2025: Prevalence, Numerical Estimates, and Projections. Diabetes Care 1998;1:1414-31
2. Amos A, McCarthy D, Zimmet P. The Rising Global Burden of Diabetes and Its Complications: Estimates and Projections to the Year 2010. Diabet Med 1997;14(suppl 5):S1-85
3. The Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
4. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
5. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97
6. Papoz L. Utilization of drug sales data for the epidemiology of chronic diseases: the example of diabetes. The EURODIAB Subarea C Study Group. Epidemiology 1993;4:421-7
7. De Beaufort C, Michel G, Haas N, Wirion R, Glaesener G. Consommation des médicaments anti-diabétiques au Grand-Duché de Luxembourg. Bull Soc Sci Med Grand Duché de Luxembourg 1991;2:5-9
8. Bergman U, Sjöqvist K. Measurement of drug utilization in Sweden: methodological and clinical implications. Acta Med Scand 1984;683:15-22
9. Stika L. Patterns in drug utilization - national and international aspects: anti-diabetic drugs. Acta Med Scand 1984;683:53-7
10. Fontbonne A, Papoz L, Eschwege E. Drug sales data and prevalence of diabetes in France. Rev Epidemiol Sante Publique 1986;34:100-5
11. nd Ed. New York, John Wiley & Sons Inc 1973
12. Sartor F, Walckiers D. Estimate of disease prevalence using drug consumption data. Am J Epidemiol 1995;141:782-7
13. Mooy JM, Grootenhuis PA, De Vries H, et al. Prevalence and determinants of glucose intolerance in a Dutch caucasian population: The Hoorn study. Diabetes Care 1995;18:1270-3
14. Michel G, Giuliani A, Keipes M, Steil S, Hansen D. Screening for non-insulin-dependent diabetes in Luxembourg. Diabetologia 1998;41(suppl 1):A122
15. EURODIAB ACE Study Group. Variation and trends in incidence of childhood diabetes in Europe. Lancet 2000;355:873-6
16. UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65